6 – June – 2023 – AFP
Saynis yahano ayaa ku shiray magaalada Chicago ee dalka Maraykanka kulan ay isugu yimadeen ururka American Society of Clinical Oncology (ASCO) oo ah ururka ugu wayn ee khubarada ku takhasusay kansarka.
Munaasabadan sanadlaha ah, oo la soo gabagabeynayo Talaadada, dhakhaatiirta iyo cilmi-baarayaashu waxay daaha ka qaadeen daraasado dhowr ah oo muujinaya korodhka heerka badbaadada dadka qaba marxaladaha halista ah ee cudurka, oo ay ku jiraan kansarka sambabada iyo maskaxda.
Khubaradu waxay tilmaameen tiro horumaro cilmiyeed ah oo ka caawiyay dardargelinta horumarinta daawaynta cusub iyadoo la beegsanayo molecules-ka ay soo saaraan unugyada kansarka.
“Asal ahaan fahamka bayooloojiyada cudurrada aan baraneyno waxay noo ogolaatay inaan raacno bartilmaameedyada daroogada – ka-hortagga ama xannibaadaha kuwaas oo la abuuri karo si ay u raacaan qodobbada nugul ee gaarka ah,” cilmi-baarista kansarka Maryam Lustberg ayaa u sheegtay Al Jazeera.
In kasta oo ay jiraan “horumaro xiiso leh”, ayay sheegtay in cilmi-baaris qoto-dheer loo baahan yahay si “loo helo daawaynta saxda ah ee bukaanka saxda ah wakhtiga saxda ah”. Lustberg ayaa sidoo kale tilmaantay in “farqiga caalamiga ah” ee dawooyinkan ay yihiin “mid aad looga naxo”, isaga oo tixraacaya sinnaan la’aanta iyo caqabadaha sii kordhaya ee helitaanka daawaynta
Kansarka sambabada
Waa kuwan qaar ka mid ah ogaysiisyada kulanka ASCO ee leh khubarada ugu xiisaha badan
Mid ka mid ah natiijooyinka tijaabada ee buuqa ka dhaliyay Chicago ayaa sare u qaaday rajada laga qabo hub cusub oo looga hortago kansarka sanbabada, kaasoo ah kan ugu dhimashada badan dhammaan kansarrada.
Daawaynta osimertinib ayaa la tusay inay kala badh ka yarayso halista dhimashada nooc gaar ah oo kansarka sanbabada ah marka la qaato maalin kasta qaliinka ka dib si meesha looga saaro burada.
Waxaa soo saaray kooxda dawooyinka ee AstraZeneca, kaniiniga maalinlaha ah wuxuu bartilmaameedsadaa bukaannada qaba kansarka unugyada aan yareyn – illaa hadda nooca ugu badan – iyo sidoo kale isbeddelka soo-dhoweynta korriinka koritaanka epidermal, ama EGFR.
Iris Pauporte, oo ah madaxa cilmi-baarista ee Ururka La-dagaallanka Kansarka ee Faransiiska, ayaa u sheegay wakaaladda wararka ee AFP in horusocodkani uu ahaa “rayad weyn oo rajo ah” oo lagu daweynayo kansarka sambabada unugyada aan yareyn, kaas oo horumarkiisu uu gaabis ahaa.
Muriel Dahan, oo ah madaxa cilmi-baarista Unicancer, ayaa sheegay in haddii natiijada la xaqiijiyo, ay “bedesho” dhaqanka caadiga ah ee daaweynta kansarka noocaan ah.
Tijaabada habaysan ee isu-beddelka EGFR waxay sidoo kale noqon doontaa lagama maarmaan bukaannada kansarka sanbabada, ayay raacisay.
Kansarka maskaxda
Daawaynta kale, oo loo yaqaan vorasidenib, ayaa la ogaaday inay si weyn u dheeraynayso badbaadada horumarka bilaashka ah ee bukaanada qaba glioma buro maskaxda, marka loo eego natiijooyinka tijaabada caafimaad.
Kiniinka maalinlaha ah, oo ay soo saartay shirkadda farmasiga ee Faransiiska Servier, ayaa ujeedadeedu tahay in la xannibo enzyme ka masuulka ah horumarka kansarka maskaxda qaarkood oo si gaar ah u adkeyd in la daweeyo.
Fabrice Andre, oo ah madaxa cilmi baarista xarunta kansarka ee Gustave Roussy ee Faransiiska, ayaa yiri “daawa saxda ah waxay albaabka u furaysaa cudur aan ilaa hadda waxba ka jirin”.
“Waxay la macno tahay in sayniska uu xannibi karo xaaladaha musiibada ahaa,” ayuu u sheegay AFP
Dahan oo ah dhakhtarka kansarka ayaa sheegay in ay muhiim tahay in la “taxadiro” laakiin waxa uu intaa ku daray in “tani ay noqon karto heerka cusub ee daaweynta – taas oo ku xidhan tijaabooyin dheeraad ah
Kansarka naasaha”
Natiijooyinka tijaabada hordhaca ah ayaa sidoo kale laga sii daayay Chicago waxay muujisay in dawada ribociclib ay hoos u dhigtay halista kansarka naasaha ee soo noqnoqda 25 boqolkiiba koox weyn oo ka badbaaday marxaladda hore.
Daawada, oo ay soo saartay Swiss farmashiyaha Novartis, ayaa horeyba si ballaaran looga ansixiyay adduunka oo dhan. Waxaa lagu tijaabiyay iyadoo lagu daray daawaynta hormoonnada.
Khabiirka ASCO Rita Nanda ayaa sheegtay inay ahayd “tijaabo caafimaad oo aad muhiim u ah oo beddeleysa”.
Kansarka ilmo-galeenka
Waxa kale oo jiray war wanaagsan oo loogu talagalay bukaannada qaba kansarka ilmo-galeenka ee marxaladda hore oo leh khatar yar oo horumar ah,
Ma jirin khatar ka weyn oo uu kansarku dib ugu soo laabanayo bukaanada qaata ilmo-galeenka fudud, kaas oo ilmo-galeenka iyo afka ilmo-galeenka laga saaro, marka loo eego qalliinka xagjirka ah, kaas oo qaybta sare ee xubinta taranka sidoo kale laga saaro, marka loo eego wajiga saddexaad ee tijaabada.
The League Against Cancer’s Pauporte ayaa sheegay in tani ay tahay “war wanaagsan”, isaga oo intaa ku daray in “ay muujinayso in aysan ahayn kaliya horumarka ku lug leh daawooyinka ee muhiimka ah.
Kansarka ugxan-sidaha
Tijaabo ayaa sidoo kale lagu soo bandhigay ASCO waxay muujisay in qaadashada daawaynta antibody-ga mirvetuximab soravtansine ay si weyn u wanaajisay heerka badbaadada bukaanada qaba kansarka ugxan-sidaha, oo ah nooca kansarka gaar ahaan dilaaga ah.
Khabiirka ASCO Merry Jennifer Markham ayaa sheegtay in daawadu “ay muujinayso horumarka ayna rajo siinayso bukaanadan”.
Kansarka malawadka
Natiijooyinka daraasadda ee laga sii daayay Chicago waxay muujiyeen in bukaannada qaba kansarka malawadka maxalliga ah ay heli karaan kiimoterabi iyaga oo aan helin daawaynta shucaaca ka hor inta aan la samayn qalliin.
Tani waxay bukaanada ka badbaadinaysaa waxyeelada shucaaca, oo ay ku jiraan daal, aragga oo qallafsan, madax-xanuun, iyo lalabo.
Tallaalada lagu daweeyo kansarka jira ayaa muddo dheer hadaf u ahaa bulshada caafimaadka.
Daraasado horudhac ah oo lagaga dhawaaqay kulanka ASCO ayaa ku lug lahaa tallaalada lagu beegsanayo kansarka sanbabada, kansarka madaxa iyo qoorta, glioblastoma buro maskaxda iyo fayraska HPV ee kansarka.
Christophe Le Tourneau, oo ku takhasusay cilmiga Kansarka ee Machadka Curie ee Faransiiska, oo soo bandhigay daraasad ku saabsan tallaalka nooc ka mid ah HPV, ayaa sheegay in “horumar tignoolajiyadeed oo la taaban karo” laga sameeyay aagga dhowaan.
“Tallaallada daweynta, waxaan uga hadalnaa iyaga oo aad iyo aad u badan, waxaana jira tijaabooyin badan oo badan oo socda,” ayuu yidhi.
AFP